AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-498-3300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$474 million
Profitability
Miscellaneous
Employees467
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions
What is AMAG Pharmaceuticals' stock symbol?
AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."
How were AMAG Pharmaceuticals' earnings last quarter?
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) posted its earnings results on Wednesday, August, 7th. The specialty pharmaceutical company reported ($1.28) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $0.62. The specialty pharmaceutical company had revenue of $78 million for the quarter, compared to analyst estimates of $90.72 million. AMAG Pharmaceuticals had a negative return on equity of 31.31% and a negative net margin of 64.33%. The company's quarterly revenue was down 46.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.75) earnings per share. View AMAG Pharmaceuticals' Earnings History.
When is AMAG Pharmaceuticals' next earnings date?
What guidance has AMAG Pharmaceuticals issued on next quarter's earnings?
AMAG Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $325-355 million, compared to the consensus revenue estimate of $368.49 million.
What price target have analysts set for AMAG?
8 analysts have issued 1 year price objectives for AMAG Pharmaceuticals' shares. Their forecasts range from $9.00 to $21.00. On average, they expect AMAG Pharmaceuticals' share price to reach $15.38 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price. View Analyst Price Targets for AMAG Pharmaceuticals.
What is the consensus analysts' recommendation for AMAG Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AMAG Pharmaceuticals.
What are Wall Street analysts saying about AMAG Pharmaceuticals stock?
Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Our $16 price target for AMAG is based on our sum-of-the-parts NPV valuation based on each of the company’s assets; we value the company’s commercail assets, and pipeline assets, ciraparantag ($9.07) and AMG-423 ($1.75) and deduct unallocated R&D and corporate expenses ($10.78). We have negligible value for Intrarosa and MuGard. Our valuation model utilizes a discount rate of 10.4% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%). We adjust each pipeline indication for probability of success with ciraparantag at 50% (adjusting for risk of ultimate approval as well as probability of establishing differentiated profile); and AMAG-423 at 33%." (8/8/2019)
- 2. According to Zacks Investment Research, "AMAG reported wider than expected loss and sales missed estimates in the first quarter of 2019. The company’s drug-Makena’s generic hit the market in July 2018, which pulled down the drug’s sales. Feraheme currently competes with IV iron replacement therapies like Venofer, Injectafer, Ferrlecit and their generic versions, among others. Shares of the company have underperformed the industry year to date. However, the FDA approved the label expansions of Feraheme and Makena, and accepted the NDA for Vyleesi with an action date of June 23, 2019 bodes well for the company. Meanwhile,the company broadened its product pipeline by adding two promising development-stage assets — AMAG-423, an orphan drug for the potential treatment of severe preeclampsia and thein-licensing of Intrarosa. The company also divested the Cord Blood Registry (CBR) business and strengthened its balance sheet." (6/20/2019)
- 3. Cantor Fitzgerald analysts commented, ": We reiterate our Neutral rating and are lowering our PT to $14 from $17. Failure of the post-approval Makena trial is a clear setback for the company. We suspect investors may be increasingly drawn to the stock as one to own given the subsequent devaluation, but that longer-term investing requires some framing of the commercial impact. We believe the trial result reinforces the importance of the next 12-18 months for AMAG to demonstrate that existing and pipeline assets can adequately replace lost Makena revenue." (3/14/2019)
Has AMAG Pharmaceuticals been receiving favorable news coverage?
Press coverage about AMAG stock has been trending very negative on Thursday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of -3.1 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for AMAG Pharmaceuticals.
Who are some of AMAG Pharmaceuticals' key competitors?
Some companies that are related to AMAG Pharmaceuticals include Insmed (INSM), Aimmune Therapeutics (AIMT), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), Eidos Therapeutics (EIDX), BELLUS Health (BLUSF), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), Zymeworks (ZYME), Turning Point Therapeutics (TPTX) and Innoviva (INVA).
What other stocks do shareholders of AMAG Pharmaceuticals own?
Who are AMAG Pharmaceuticals' key executives?
AMAG Pharmaceuticals' management team includes the folowing people:
- Dr. William K. Heiden, CEO, Pres & Director (Age 59)
- Mr. Edward H. Myles, Exec. VP, CFO & Treasurer (Age 47)
- Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Corp. Sec. (Age 47)
- Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 53)
- Ms. Linda S. Lennox, VP of Investor Relations & Corp. Communications
Who are AMAG Pharmaceuticals' major shareholders?
AMAG Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.08%), Robeco Institutional Asset Management B.V. (0.05%) and Fox Run Management L.L.C. (0.04%). Company insiders that own AMAG Pharmaceuticals stock include Armistice Capital, Llc, Camber Capital Management Lp, Elizabeth Scott Bolgiano, Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.
Which institutional investors are selling AMAG Pharmaceuticals stock?
Which institutional investors are buying AMAG Pharmaceuticals stock?
AMAG stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Fox Run Management L.L.C.. Company insiders that have bought AMAG Pharmaceuticals stock in the last two years include Armistice Capital, Llc, Camber Capital Management Lp, Elizabeth Scott Bolgiano, Julie Krop and William K Heiden. View Insider Buying and Selling for AMAG Pharmaceuticals.
How do I buy shares of AMAG Pharmaceuticals?
Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is AMAG Pharmaceuticals' stock price today?
One share of AMAG stock can currently be purchased for approximately $11.17.
How big of a company is AMAG Pharmaceuticals?
AMAG Pharmaceuticals has a market capitalization of $378.77 million and generates $474 million in revenue each year. The specialty pharmaceutical company earns $-65,760,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis. AMAG Pharmaceuticals employs 467 workers across the globe.View Additional Information About AMAG Pharmaceuticals.
What is AMAG Pharmaceuticals' official website?
How can I contact AMAG Pharmaceuticals?
AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]
MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.
